KU Fights Cancer

The University of Kansas is emerging as a leader in the fight against cancer. Last month, KU announced the opening of a Phase I clinical trial for a new ovarian cancer drug, Nanotax, developed by researchers at the KU Cancer Center. The new drug is a reformulation of the common chemotherapy drug, Paclitaxel, which is administered intravenously. Unpleasant side effects have been attributed to the solvent mixed with the drug for delivery.

The development of Nanotax by KU researchers was significant for two reasons. By breaking Paclitaxel to nanopartical form, they were able to mix it with water, allowing the drug to be administered to a patient's abdomen.

"By removing the source of the negative side effects, we believe Nanotax will be a less toxic treatment," said Roy Jensen, director of the KU Cancer Center.

Nanotax is also significant because it is KU's first "bench to bedside" drug, which means it was discovered, tested and brought to clinical trial by KU scientists at the KU Cancer Center. This fact significantly enhances KU's quest to obtain NCI designation for the KU Cancer Center. Kansas City remains the largest metropolitan area in the U.S. not served by an NCI designated Comprehensive Cancer Center, and the university has made attaining the designation it's top priority.

KU has had a lot of big wins this past year, but this news was truly worth celebrating.